China Medical System (HKG:0867) received Chinese regulatory approval to begin human trials of CMS-D017, according to a Hong Kong bourse filing Tuesday.
The firm plans to evaluate the drug's safety and tolerability in healthy participants in China.
The medicine is being developed to treat complement-mediated kidney diseases.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments